Consider a practice group like this one. Dr. Marcus Feld runs eleven locations across suburban Ohio, roughly $19M in collections, and he decided in January that this was the year. The first call with a buyer went beautifully. By March there was a letter of intent on his desk with a number he had not let himself imagine, and he told his wife it would all be done by summer. It closed in November. Somewhere in month seven, buried in requests for new patient source data he could not cleanly produce, he stopped feeling like a seller and started feeling like a witness. If you have never checked what this looks like in your own practice, you are standing where they stood.
The offer arrives faster than the close. That is the part nobody prepares you for. You spend two years wondering whether to sell, one afternoon getting excited about a number, and then eleven months answering questions about it. Somewhere in month six you stop recognising your own group in the spreadsheets being passed around a conference room you have never sat in. This is not an article about whether to sell. It is about the clock, and about what the clock quietly does to your leverage. Because the one factor that moves both the closing date and the final number is something most owners only start fixing after the letter of intent is already signed.
Why does the timeline feel shorter in your head than it is on paper?
Picture what you imagine when you imagine selling. A conversation. A number. A signature. A wire. Three months, maybe four, and then a different kind of life. The reality for most owner-operators is six to twelve months from the first serious conversation to a funded close, and the back half of that stretch is almost entirely verification. Not negotiation. Verification.
The gap between those two pictures is where owners get hurt. You budget your attention for a sprint and then find yourself ten months in, still producing, still managing hygiene coverage, still fielding document requests at nine at night. Your group is one of 201,000+ US practices in a $179.4B market, and the buyer across the table is looking at several of them at once. Their timeline is a portfolio. Yours is your life's work.
Understand that asymmetry early. You feel every week of this process. They feel a pipeline. The owners who come out well are the ones who priced that difference in before they picked up the phone.
What actually happens between the first conversation and the letter of intent?
This is the fast part, and it is the part that fools people. A conversation, a mutual non-disclosure agreement, a summary of your financials, a discussion of adjusted earnings and what add-backs the buyer will accept. If your books are clean and your operational story is coherent, you can be holding a letter of intent inside 30 to 60 days.
It feels like momentum. It is really a hypothesis. The letter of intent is the buyer saying: if everything you have told us is true, this is roughly what we would pay. The word doing the heavy lifting in that sentence is if.
One clause deserves your attention before you sign it: exclusivity. The letter of intent typically takes you off the market for the length of diligence, which means the moment you sign, your only remaining leverage is the quality of what you can prove. Every alternative buyer goes quiet. Sign that clause with your evidence already assembled, not with a plan to assemble it.
Your emotional experience in these weeks is close to euphoria, and that is exactly the risk. You will start making plans. You will mentally spend a portion of it. You will tell two people who were not supposed to know. Then diligence opens and the tone changes completely, and the drop feels personal even though it is entirely procedural. Expect the shift. It is not a sign the deal is failing.
Why does due diligence take longer than anyone tells you?
Budget 90 to 150 days, and be pleasantly surprised if it runs shorter. A quality of earnings review will rebuild your profit and loss statement from the ground up. Chart audits will sample your clinical documentation. Someone will read every lease, every associate agreement, every payer contract, every payroll register going back three years.
The delays almost never come from the buyer being slow. They come from the seller being asked for something that does not exist in retrievable form. A production report by provider by procedure by location, monthly, for 36 months. New patient counts split by source. Hygiene reappointment rates that reconcile to the schedule rather than to memory.
Notice what separates a clean answer from a costly one. It is rarely the number itself. It is whether the number can be traced back to the system that produced it. A buyer who can follow a new patient from the source that generated them, through the schedule, into the ledger, stops asking. A buyer handed a figure with no path behind it starts sampling, and sampling takes months.
Staffing gets its own microscope. With 33.9% of practices actively recruiting hygienists, a buyer will want to know whether your hygiene production is a durable asset or a coverage problem waiting to surface. Your answer needs documentation behind it. If the honest response is that it depends on one person, that becomes a diligence finding, and diligence findings become price adjustments.
What is the buyer really checking when they look at your patient demand?
Every acquirer is buying a forecast. Trailing revenue tells them what happened. New patient origin tells them what happens next, which is the only thing that matters to the people funding the purchase.
So they will ask a deceptively simple question: where do your new patients come from? Not the referral pipeline you built in 2014. The ones who walked in last month.
Here is where the ground has moved under most groups. There are now 432,000 dental searches performed through AI systems every month, and 70% of practices are effectively invisible to those systems. That figure is drawn from The Dental Index national practice audit, and it should stop you cold if you are preparing to sell. Roughly 82% of local searches end in a Maps interaction, and if your locations are not surfacing there, your new patient flow depends on habits and history rather than on discovery.
A buyer reads that as concentration risk. Your growth story becomes a claim without evidence. If you want to understand how buyers now evaluate DSO acquisition targets, start with the question of whether your demand is findable or merely inherited.
Why do deals slow down at exactly the point you stop paying attention?
Month seven is where deals go quiet and dangerous. You have answered four hundred questions. Your chief financial officer is exhausted. You have been in the process long enough that you have stopped running the group with both hands, and the numbers start to show it.
This is the trap. Diligence measures a moving target. If collections soften while you are distracted, the buyer is not obligated to ignore it. They will reprice against current trailing performance, and the conversation you have in month eight is very different from the one you had in month three.
Owners describe this as bad luck. It is closer to physics. Attention left the operation and the operation responded.
Watch your own calendar for the tell. When the deal starts occupying the hours you used to reserve for the practice, the practice is already paying for it. The groups that hold their numbers through month seven are almost always the ones where new patients never depended on the owner's attention to begin with.
The protection is unglamorous: someone other than you owns the deal process, and your production and patient acquisition continue exactly as they did before anyone made an offer. A group whose new patient flow is systematic rather than founder-driven survives this stretch intact. A group where the owner personally is the demand engine will not.
Does preparing before the process really change the closing date?
It changes it more than anything else you control. Not because preparation removes steps, but because it changes what each step costs you.
An unprepared seller experiences diligence as a series of emergencies. Every request triggers a scramble, and each scramble adds days. A prepared seller experiences the same requests as retrieval. The document already exists. The number already reconciles. Weeks come off the calendar not through negotiation, but through the simple absence of friction.
The preparation gap is measurable in visibility terms. The average practice scores under 40 out of 100 on AI readiness, and only 8% clear 65. If your group sits in the majority, you are not just unfindable to patients. You are unprovable to buyers, because there is no external evidence supporting the growth narrative in your deck.
Consider what that does to the room. Preparation shifts who is explaining things to whom. Unprepared, you spend ten months justifying your own business. Prepared, the buyer spends those months confirming what you already documented. Same process, entirely different balance of power.
What does an unprepared group look like inside a data room?
It looks like a business that might be excellent and cannot demonstrate it. The clinical quality is real. The team is loyal. The story simply has no verifiable spine.
Buyers reduce that ambiguity to price and structure. More earn-out, less cash at close, longer holdback, more time.
| What the buyer checks | Group with clear positioning | Group without | Effect on the deal |
|---|---|---|---|
| AI search visibility | Among the 8% scoring above 65 on AI readiness | Within the 70% invisible to AI systems | Growth forecast supported or questioned |
| Local discovery | Complete profiles drawing up to 7x more clicks | Incomplete listings across locations | New patient flow reads durable or fragile |
| Patient origin data | Documented against 82% of searches ending in Maps | Anecdotal and owner-recalled | Diligence compresses or extends |
| High-value case mix | Implants at 8.5% annual growth, $4,500 average | Undifferentiated general production | Multiple applied at the top or bottom of range |
Source: The Dental Index national practice audit · 2026
Read that table as a buyer would. Every row is a question about risk, and every gap you leave gets priced.
Notice what none of those rows measure: how good you are. Clinical excellence is assumed rather than rewarded. What gets rewarded is proof that demand arrives without you, and that proof lives outside your walls, in whether patients can find your locations at all.
The letter of intent is the emotional high point of the deal. Everything after it is someone checking whether you were telling the truth.
How does your visibility affect the multiple, not just the schedule?
Speed is the visible benefit. Valuation is the real one.
Buyers pay for growth they believe will continue without you. Complete, well-maintained local profiles generate up to 7x more clicks than incomplete ones, and patients arriving through AI-driven discovery book high-value treatment at two to three times the rate of other channels. Your group does not just look busier. It looks like it converts differently, and the case mix proves it.
That matters because the segments carrying the market are the ones tied to considered decisions. Implants are growing 8.5% annually at a $4,500 average case value. Cosmetic sits at 6.8% and $3,800. Orthodontics at 5.1% and $5,500. These are procedures patients research before they choose, which means they flow toward practices that are actually findable during the research.
The average solo practice leaves roughly $147,000 unrealised each year through poor visibility. Multiply that across eleven locations and you are not describing a missed opportunity. You are describing a permanent reduction in the earnings base the buyer applies a multiple to. Your positioning does not just fill chairs. It sets the arithmetic of your exit.
What is closing fatigue and why does it cost you money?
Around month eight something changes in you. The excitement is long gone. The lawyers are arguing about representations you did not know existed. Your team senses something. You have answered the same question three times in three formats. And a thought arrives that you would have found absurd in month one: I would accept almost anything to be finished.
That is closing fatigue, and buyers who transact regularly understand it perfectly well. It is precisely when working capital pegs get renegotiated, when holdback percentages creep up, when an indemnity cap moves in a direction you would have contested in the spring.
You will not out-discipline exhaustion. What you can do is shorten the runway. Every week you remove from diligence is a week your judgment stays sharp, and the only reliable way to remove those weeks is to have arrived with your evidence already built.
Fatigue is not a character flaw. It is the predictable cost of a long process, and preparation is the only real anaesthetic available to you.
The deal is not a negotiation, it is an audit
Owners prepare to argue for their number and are surprised to find nobody is arguing. The operators who do well understand that after the letter of intent, price moves almost entirely on what can be verified, not what can be asserted. They stop preparing arguments and start preparing evidence.
Your visibility is a balance sheet item
Most owners file patient discovery under operating expense, something that either works or does not in any given quarter. The groups that exit well see it differently. They recognise that a documented, findable demand engine is the asset the multiple actually attaches to, and they build it years before anyone asks.
Time on the clock is leverage leaving the room
Every additional month of diligence transfers a little more power to the buyer, because you are the only party at the table who gets tired. The sellers who hold their terms are rarely the toughest negotiators. They are the ones whose preparation made the process short enough that fatigue never arrived.
Buyers are not buying your past, they are buying your next owner's future
The question behind every diligence request is whether this group grows once you are no longer personally driving it. A practice whose new patients arrive through systems survives that question. A practice whose new patients arrive through the founder's relationships does not, and the structure of the deal will say so.
How long should you prepare before you talk to a buyer?
Twelve to eighteen months, if you have the luxury of choosing. Not because the paperwork takes that long, but because the thing buyers pay a premium for is a trend, and a trend needs time to become visible.
A single strong quarter of new patient growth is noise. Six consecutive quarters of documented, traceable patient acquisition is an asset. You cannot manufacture the second one in the middle of diligence, which is exactly when most owners first realise they need it.
There is a quieter reason to start early. Preparation changes what you learn about your own group. Plenty of owners discover during diligence that they never actually knew where last quarter's new patients came from, and finding that out with a buyer in the room is expensive. Finding it out eighteen months earlier is just information, and information you still have time to act on.
This is why the timing conversation and the visibility conversation are the same conversation. Rebuilding how your locations appear in patient discovery is not a deal task. It is an operating decision made a year earlier, whose value shows up on a closing statement. The way a group signals its value to patients before they ever call is slow to build and impossible to fake under deadline.
If you are three years out, you have every advantage available. If you are three months out, you are negotiating with what already exists.
What does the timeline look like when your positioning is already clear?
It looks like a shorter, calmer, more expensive deal.
The letter of intent still takes 30 to 60 days, but it is priced on a story the buyer can already partially verify from outside your data room. Diligence compresses toward the front of the 90 to 150 day range because the difficult questions have documented answers waiting. And critically, the questions themselves change character. Instead of proving your new patient flow is real, you are discussing how it scales across their platform.
That shift is the entire point. A prepared group is not being investigated. It is being courted. With DSO ownership now at 32% of the market, acquirers are not short of targets. What they are short of is targets whose growth is legible without a forensic exercise.
You will still be tired at the end. It will still take longer than you hoped. But you will arrive at the closing table having negotiated from evidence rather than from assertion, and every material term of your deal reflects which of those two positions you were standing in.
Here is the part that connects to your Tuesday, not just your exit. Everything a buyer scrutinises about your growth is the same thing a patient encounters when they search for an implant consultation two miles from your Westerville location. If the AI systems fielding 432,000 dental searches a month cannot identify your group, and your locations are not the ones surfacing in Maps, then your future earnings rest on habit rather than on discovery. Buyers price that. Patients simply choose someone else. Clear positioning is what makes both AI search and local ranking work, and invisible positioning produces an invisible practice regardless of how hard you have worked or how much you have spent.